Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EWZST
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2020252015A1 ADCLP-2
|
|||||
| Synonyms |
ADCLP-2
Click to Show/Hide
|
|||||
| Organization |
SUTRO BIOPHARMA, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1-10
|
|||||
| Structure |
|
|||||
| Antibody Name |
mAb42
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
DBCO-SO3-PEG4-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
DBCO-L-CysteicAcid-PEG4-VKG-Exatecan
|
|||||